SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form F-3 - Registration statement by foreign private issuers:
SEC Accession No. 0001213900-22-022533
Filing Date
2022-04-29
Accepted
2022-04-29 08:14:36
Documents
10

Document Format Files

Seq Description Document Type Size
1 REGISTRATION STATEMENT ea159018-f3_enlivextherap.htm F-3 261219
2 OPINION OF FISCHER (FBC & CO.) ea159018ex5-1_enlivextherap.htm EX-5.1 22951
3 OPINION OF GREENBERG TRAURIG, P.A. ea159018ex5-2_enlivextherap.htm EX-5.2 20272
4 CONSENT OF YAREL + PARTNERS, INDEPENDENT REGISTERED CERTIFIED PUBLIC ACCOUNTING ea159018ex23-1_enlivextherap.htm EX-23.1 2923
5 FILING FEE TABLE ea159018ex-fee_enlivextherap.htm EX-FILING FEES 19635
6 GRAPHIC image_001.jpg GRAPHIC 122293
7 GRAPHIC ex5-1_001.jpg GRAPHIC 19485
8 GRAPHIC ex5-2_001.jpg GRAPHIC 3306
9 GRAPHIC ex23-1_001.jpg GRAPHIC 7162
10 GRAPHIC ex23-1_002.jpg GRAPHIC 5684
  Complete submission text file 0001213900-22-022533.txt   546148
Mailing Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042
Business Address 37 DEREH MENACHEM BEGIN ST. 15TH FLOOR TEL AVIV L3 6522042 972 (0) 3 7326616
Enlivex Therapeutics Ltd. (Filer) CIK: 0001596812 (see all company filings)

IRS No.: 000000000 | State of Incorp.: L3 | Fiscal Year End: 1231
Type: F-3 | Act: 33 | File No.: 333-264561 | Film No.: 22870411
SIC: 2834 Pharmaceutical Preparations